Antibodies
9 February 2015
Compugen Presents New Results Supporting CGEN-15049 as Potential Cancer Immunotherapy Target7 February 2015
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Treatment of Diabetic Retinopathy in People With Diabetic Macular Edema5 February 2015
OncoMed Initiates Dosing in Phase 2 Clinical Trial of Demcizumab for the Treatment of Non-Small Cell Lung Cancer4 February 2015
Merus starts Phase I/II clinical trial for MCLA-128, an ADCC-enhanced bispecific antibody for solid tumors2 February 2015
Lpath Submits Investigational New Drug Application for Lpathomab for Neuropathic Pain2 February 2015
Acorda Announces Safety and Tolerability Data from First Clinical Trial of Remyelinating Antibody in Multiple Sclerosis2 February 2015
FIRST PATIENT ENROLLED IN THE NEW DRUGS 4 BAD BUGS PROGRAM29 January 2015
BIOCAD – World Leader in Biosimilar Rituximab Sales29 January 2015
Xencor Reports Top-line XmAb®5871 Phase 1b/2a Results Showing Promising Clinical Activity in Rheumatoid Arthritis29 January 2015
Xencor Reports XmAb®7195 Top-line Interim Phase 1a Results Showing Rapid Reduction of Serum IgE in Healthy Volunteers26 January 2015
Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA23 January 2015
Bayer Receives Recommendation for Approval for New Treatment Option with Aflibercept Solution for Injection in EU22 January 2015
Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients21 January 2015
European Medicines Agency Accepts Samsung Bioepis’ Enbrel(R) Biosimilar Candidate, SB4, for Regulatory Review20 January 2015
Immunomedics Reports Phase 1/2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Metastatic Gastrointestinal Cancers20 January 2015
BioInvent’s BI-1206 antibody to enter collaborative Phase l/ll trial funded and conducted by Cancer Research UK, CRT and LLR15 January 2015
Arsanis Researchers Report Broadly Neutralizing Cross-Reactive Monoclonal Antibody Targeting Multiple Staphylococcus aureus CytotoxinsNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports